Business Wire

CARBIOS

26.1.2023 06:46:34 CET | Business Wire | Press release

Share
Carbios Strengthens Executive Committee in Pivotal Year for Industrial and Commercial Development

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005432/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(L-R): Martine BRISSET (General Manager Biodegradation Division, Senior Vice President of Carbios Group, and Executive Committee Member) and Delphine DENOIZE (Innovation Programs Funding, Regulation and LCA Director, and Executive Committee Member)

Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, has strengthened its leadership team with the appointment of Martine BRISSET as Senior Vice President from 1 January 2023. Martine will manage the Biodegradation Division and supervise the Human Resources, Legal, Regulatory, Project Management, Quality Health and Safety departments. Martine BRISSET joins the Group's Executive Committee, as does Delphine DENOIZÉ, who remains Innovation Programs Funding, Regulation and LCA Director with an expanding team.

"Over the past six months, our teams have grown significantly in order to achieve our ambitious targets, and I am very pleased to appoint Martine and Delphine to the Executive Committee," commented Emmanuel LADENT, Chief Executive Officer of Carbios. "Their proven track records, notably within the Carbios Group, strengthen the top management’s expertise and reinforces the diversity of skills needed to succeed in this pivotal year for Carbios’ industrialization and commercialization.”

Martine BRISSET, Senior Vice President of Carbios : “After having supervised the production of thousands of tons of plastic destined for the packaging sector, I am now focused on reducing plastic pollution with our biodegradation and biorecycling solutions. I'm very excited to take on this awesome and exciting challenge, one that makes sense for future generations and for industry."

Martine BRISSET has over 30 years of General Management experience in major international groups within the plastic and paper packaging industry, most notably at Amcor, Huhtamaki, Linpac and Klockner Pentaplast. Since 2021, she has held the position of General Manager of Carbiolice in order to integrate this high-potential subsidiary dedicated to biodegradation within the Carbios Group. In her new position as Senior Vice President of Carbios, her main mission will be to successfully deploy the biodegradation technology, facilitate the international expansion of Carbios' activities, organise the recruitment and training of the Group's employees. With numerous recruitments planned throughout the company in 2023, building Carbios’ attractivity will be a strategic topic.

Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director : "What drives me is the satisfaction of seeing a project through, from concept to reality. At Carbios, all our projects have a positive impact on the environment, and it’s rising to this challenge that makes me passionate about my work. By becoming a member of the Executive Committee, I will support these projects even more enthusiastically, in terms of their structuring and funding, but also in terms of their regulatory compliance and environmental performance.”

After several years working in innovation within the agricultural industry, it was during her time at Céréales Vallées cluster that Delphine DENOIZÉ discovered and assisted in the creation of Carbios. She joined the company in 2016 and was one of its first twenty employees. Initially in charge of Innovation Funding and Regulation, then Project Management for PET biorecycling, she now oversees all the Group’s projects. Her responsibilities include French and European public funding for innovation, regulatory compliance of processes and products around the world, and assessment of their environmental impact through specific tools such as Life Cycle Assessment.

Executive Committee Members of Carbios Group:

  • Emmanuel LADENT, Chief Executive Officer
  • Lionel ARRAS, Industrial Development Director
  • Mathieu BERTHOUD, Sourcing and Public Affairs Director
  • Pascal BRICOUT, Chief Strategy and Financial Officer
  • Martine BRISSET, General Manager Biodegradation Division and Senior Vice President of Carbios Group
  • Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director
  • Stéphane FERREIRA, Chief Business Officer
  • Lise LUCCHESI, Intellectual Property Director
  • Prof. Alain MARTY, Chief Scientific Officer

Visit Carbios’ website for biographies of each individual member: https://www.carbios.com/en/governance/

About Carbios

Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.

In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products.

The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.

For more information, please visit carbios.com / Twitter: Carbios / LinkedIn: Carbios / Instagram: insidecarbios

Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the French version shall prevail

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005432/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye